Cytotoxic drugs are high potent drug products that has application in the treatment of cancer. Cytotoxic drugs contract manufacturing are the services that are utilized by the pharmaceutical, biotech manufacturing companies, in order to treat chronic diseases such as cancer. For instance, new immuno-oncology therapies such as antibody-drug conjugates, which are manufactured through high potency active pharmaceutical ingredients (HPAPIs) by cytotoxic drugs manufacturing companies. These contract manufacturing firms gained operational expertise, geographic reach, and necessary infrastructure to efficiently handle cytotoxic drugs. This helps pharmaceutical and biotech firms to offer novel therapies in the quickest possible time.
The global cytotoxic drugs contract manufacturing market size was valued at US$ 6,285.2 million in 2018, and is expected to exhibit a CAGR of 9.1% over the forecast period (2019-2027).
Figure 1. Global Cytotoxic Drugs Contract Manufacturing Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing demand for targeted therapy is expected to boost the growth of the cytotoxic drugs contract manufacturing market
Cytotoxic drugs and high potency active pharmaceutical ingredients developments are the key focus areas for the manufactures globally for offering more specialized medicines especially in the field of oncology. For instance, according to the IMS institute of healthcare informatics, 2016, 586 drugs were under development for oncology treatment, with over 70 new cancer treatments (for over 20 tumor types), entered the market during 2010-2015.
Increasing investment by the market players for expansion of facility, in order to enhance its market share is one of major factors that is expected to drive growth of the cytotoxic drugs contract manufacturing market. For instance, in June 2019, Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization (CDMO), announced about the opening of a new wing at the Riverview site. U.S., dedicated for production of high potency active pharmaceutical ingredients (HPAPIs) with low occupational exposure levels (OELs). Total investment required to upgrade the site was around US$ 10 million. Moreover, in February 2013, Baxter BioPharma Solutions expanded its cytotoxic contract manufacturing facility in Halle (Westfalen), Germany. The company expanded its manufacturing capacity to 1,750 square meters. Furthermore, in July 2013, Baxter BioPharma Solutions launched a new packaging line at its Halle/Westfalen, Germany facility to support BioPharma Solutions’ cytotoxic contract manufacturing services.
Increasing adoption of acquisition and collaboration strategies by key players is expected to boost demand for cytotoxic drugs contract manufacturing over the forecast period. For instance, In November 2015, Merck KGaA (SAFC Pharma) acquired Sigma-Aldrich to expand its offerings, capabilities, geographic presence, and life sciences segment.
Figure 2. Global Cytotoxic Drugs Contract Manufacturing Market Share (%), by Production Scale, 2019 and 2027
Source: Coherent Market Insights Analysis (2019)
Cytotoxic Drugs Contract Manufacturing Market - Regional Analysis
Among regions, North America cytotoxic drugs contract manufacturing market is expected to account for the largest market share over the forecast period, owing to increasing prevalence of cancer in the region. For instance, according to the National Cancer Institute, 2016, the number of new cancer cases per year is expected to increase to 23.6 million by 2030, globally. Moreover, according to the National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024 globally.
Moreover, Europe is expected to account for significant market share in the global cytotoxic drugs contract manufacturing market over the forecast period, owing to implementation of government regulations and growing incidence of cancer in the region. For instance in 2018, according to the World Health Organization, around 4,229,662 new cases of cancer were diagnosed in Europe. Moreover, in 2016, new policy recommendations on preventing occupational exposure to cytotoxic drugs were launched in the European Parliament, which was an initiative designed to protect healthcare professionals working across the European Union. This was undertaken as unsafe handling of cytotoxic drugs could cause cancer, organ toxicity, fertility problems, genetic damage, and birth defects.
Major players operating in the global cytotoxic drugs contract manufacturing market include Lonza Group, Piramal Group, Evonik Industries AG, Novasep Holding SAS, Merck KGaA (SAFC Pharma), Baxter Biopharma Solutions, AbbVie Contract Manufacturing, Cambrex Corporation, BSP Pharmaceuticals S.p.A., CordenPharma Internatisonal, Catalent, Inc., Albany Molecular Research Inc., Evotec, WuXi AppTec Co., Ltd., Pierre Fabre Laboratories, and Dishman Group
Cytotoxic drugs contract manufacturing market has grown significantly over the last decade. Increasing incidence of cancer and increasing adoption of various growth strategies such as expansion, collaborations, and acquisitions by the key players are expected to boost market growth over the forecast period. Pharmaceutical and biotechnological companies are involved in research and development of cytotoxic drugs and high potency active pharmaceutical ingredients (HPAPIs), and in the manufacture of drugs in-house or outsource the production to other manufacturers.
Rising incidence of cancer is expected to propel the market growth over the forecast period. For instance, according to an American Cancer Society estimations, 2017, 1,688,780 people were estimated to be diagnosed with cancer and 600,920 cancer deaths were reported in the U.S.
Increasing product approval for the treatment of cancer is expected to boost growth of the global cytotoxic drugs contract manufacturing market over the forecast period. For instance, in October 2018, Catalent Pharma Solutions received the approval of U.S. Food and Drug Administration (FDA) for Verastem Oncology’s COPIKTRA (duvelisib) capsules.
Furthermore, rising adoption of contract manufacturing services by the pharmaceutical companies is expected to drive growth of the global cytotoxic drugs contract manufacturing market over the forecast period. For instance, in September 2018, GB Sciences, Inc. selected Catalent Pharma Solutions to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients (APIs) for its Parkinson’s disease therapies.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.